Severe Eosinophilic Asthma Clinical Trial
Official title:
A Real World Multicenter 48 Week Prospective Cohort Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab in Routine Care Settings in Greece
Severe eosinophilic asthma (SEA) is associated with poor disease control and compromised health-related quality of life (HRQoL), leading to a substantial psychosocial and economic disease burden. Benralizumab (Fasenra®), an interleukin (IL)-5-alpha receptor monoclonal antibody, is approved as an add-on maintenance treatment for SEA. This study aims at collecting real-world data that extend beyond the clinical effectiveness of benralizumab to the participant-reported impact of treatment on their HRQoL, sleep quality, depression, anxiety, work productivity and activity impairment, but also on treatment effectiveness. Recent technological advances in portable spirometers and wearable activity trackers (WAT) to increase physical activity for participants with asthma, even for older participants, allow this study to collect data on lung function parameters and physical activity from such devices for the first time at a country level in Greece. Using a multi-aspect approach, this study will generate real-world evidence on a broad range of both well-established clinical and novel patient-centered outcomes which are critical to the assessment of the therapeutic benefit both from the physician's and the participant's perspective. All main study outcomes will be examined at various timepoints throughout the course of the 48-week observation period, starting as early as 4 weeks after treatment initiation, thus enabling the identification of 'early' treatment responders with a closer focus on patients' physical and psychological well-being and HRQoL in addition to asthma control and lung function metrics
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
| Completed |
NCT02560610 -
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
|
Phase 2 | |
| Recruiting |
NCT06069310 -
Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
|
||
| Not yet recruiting |
NCT03652376 -
Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma
|
Phase 4 | |
| Recruiting |
NCT04542902 -
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
|
N/A | |
| Completed |
NCT05180357 -
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
|
||
| Active, not recruiting |
NCT03833141 -
Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
|
||
| Completed |
NCT05271526 -
Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
|
||
| Not yet recruiting |
NCT06302959 -
Clock Proteins as Prognostic Markers
|
||
| Completed |
NCT04159519 -
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
|
Phase 4 | |
| Completed |
NCT03907137 -
Real World Study With Benralizumab in Severe Asthma in Switzerland
|
||
| Active, not recruiting |
NCT04084613 -
Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
|
||
| Completed |
NCT04126499 -
Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
|
||
| Recruiting |
NCT06465485 -
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
|
Phase 3 | |
| Recruiting |
NCT03739320 -
A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma
|